Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance

Authors: Hannah Wang, MD^{1*}; Jacob A. Miller, MD^{2*}; Michelle Verghese, BA¹; Mamdouh Sibai, BS³; Daniel Solis, BS¹; Kenji O. Mfuh, PhD³; Becky Jiang, CLS³; Naomi Iwai, CLS³; Marilyn Mar, CLS³; ChunHong Huang, MD¹; Fumiko Yamamoto, MS¹; Malaya K. Sahoo, PhD¹; James Zehnder, MD¹; Benjamin A. Pinsky, MD, PhD^{1,3,4}

*Authors HW and JAM contributed equally to this manuscript.

Author Affiliations:

¹Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
²Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
³Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA
⁴Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

Key Words: SARS-CoV-2; COVID-19; Variant; Genotyping; RT-qPCR

Running Title: SARS-CoV-2 Variant Genotyping PCR

Corresponding Author:	Alternate Corresponding Author:

Benjamin A. Pinsky, MD, PhD	Hannah Wang, MD
3375 Hillview, Room 2913	3375 Hillview, Room 2913
Palo Alto, CA 94304	Palo Alto, CA 94304
Phone (650) 498-5575	Phone (650) 498-5575
Fax (650) 736-1964	Fax (650) 736-1964
bpinsky@stanford.edu	wangh1@stanford.edu

Summary / Key Points:

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Emergence of SARS-CoV-2 variants with concerning phenotypes is of public health interest. We developed a multiplex genotyping RT-qPCR to rapidly detect L452R, E484K, and N501Y with high sequencing concordance. This high-throughput alternative to resource-intensive sequencing enabled surveillance of L452R emergence.

ABSTRACT:

Background: Emergence of SARS-CoV-2 variants with concerning phenotypic mutations is of public health interest. Genomic surveillance is an important tool for pandemic response, but many laboratories do not have the resources to support population-level sequencing. We hypothesized that a spike genotyping nucleic acid amplification test (NAAT) could facilitate high-throughput variant surveillance.

Methods: We designed and analytically validated a one-step multiplex allele-specific reverse transcriptase polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein mutations (L452R, E484K, N501Y). Assay specificity was validated with next-generation whole-genome sequencing. We then screened a large cohort of SARS-CoV-2 positive specimens from our San Francisco Bay Area population.

Results: Between December 1, 2020 and March 1, 2021, we screened 4,049 unique infections by genotyping RT-qPCR, with an assay failure rate of 2.8%. We detected 1,567 L452R mutations (38.7%), 34 N501Y mutations (0.84%), 22 E484K mutations (0.54%), and 3 (0.07%) E484K+N501Y mutations. The assay had near-perfect (98-100%) concordance with whole-genome sequencing in a validation subset of 229 specimens, and detected B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants, among others. The assay revealed rapid emergence of L452R in our population, with a prevalence of 24.8% in December 2020 that increased to 62.5% in March 2021.

Conclusions: We developed and clinically implemented a genotyping RT-qPCR to conduct high-throughput SARS-CoV-2 variant screening. This approach can be adapted for emerging mutations and immediately implemented in laboratories already performing NAAT worldwide using existing equipment, personnel, and extracted nucleic acid.

INTRODUCTION

High transmission rates during the coronavirus disease 2019 (COVID-19) pandemic have facilitated the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The underlying genomic diversity defining these variants is indicative of natural selection of mutations with phenotypic significance.^{1–3} In particular, variants associated with increased transmission, virulence, or resistance to host, vaccine, or antiviral immunity are of significant public health concern.^{4–17} Other mutations could also potentially impact diagnostic sensitivity.¹⁸ Genomic surveillance that is representative of the newly-infected population is therefore an important tool for pandemic response.

As of March 2021, the United States Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control (ECDC), and World Health Organization (WHO) identified multiple SARS-CoV-2 lineages as variants of concern or variants of interest (VOC/VOI).^{19–21} Many share the spike protein mutations E484K (B.1.351, B.1.525, B.1.526, P.1, P.2), N501Y (B.1.1.7, B.1.351, P.1), and/or L452R (B.1.427, B.1.429), among others. Such variants have primarily been identified by targeted or whole-genome sequencing. However, due to the required resources, technical expertise, and equipment for sequencing, few public health systems have successfully coordinated timely large-scale sequencing efforts. Among individual institutions that have developed sequencing programs, there is tremendous variability in throughput, selection criteria, and methodology that confound accurate estimates of individual variant prevalence. Because the vast majority of laboratories worldwide do not have the resources required to develop and support large-scale sequencing initiatives, a complementary surveillance strategy is desirable.

Upper respiratory nucleic acid amplification tests (NAATs) are the mainstay of SARS-CoV-2 diagnosis. In contrast to sequencing, nearly all laboratories offering NAATs have equipment and trained personnel for nucleic acid extraction and real-time polymerase chain reaction. We therefore aimed to develop a highly-accessible spike genotyping NAAT for high-throughput and rapid screening of positive SARS-CoV-2 samples. We hypothesized that this assay would facilitate large-scale VOC/VOI screening and track emergence of mutations in our population. This approach enables population-based triaging of samples to centers performing sequencing analysis for lineage determination and increases access to variant surveillance.

METHODS:

Assay Design

In January 2021, the B.1.1.7, B.1.351, B.1.1.28 descendant P.1, B.1.1.28 descendant P.2, and B.1.427/B.1.429 variant lineages were of primary global and local epidemiologic significance. Informed by recent studies describing mutation phenotypic significance and convergent evolution, we elected to begin

screening our population for the spike N501Y (B.1.1.7, B.1.351, P.1), E484K (B.1.351, P.1, P.2), and L452R (B.1.427/B.1.429) mutations.

We therefore designed a one-step multiplex allele-specific reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) to detect these three non-synonymous single nucleotide variants in the spike gene (N501Y: RefSeq NC_045512 23063A>T; E484K: 23012G>A, L452R: 22917 T>G). We selected the wild-type N501 allele (23063A) to serve as a control for those samples that lack any of the targeted mutations.

To permit single reaction multiplexing, we designed primer sets and dual-labeled hydrolysis probes to maximize each probe's mismatch- ΔT_m while maintaining probe specificity and a sufficiently high annealing temperature (Supplementary Table 1). This 2-7°C decrease in each probe's annealing temperature (ΔT_m) when binding SARS-CoV-2 cDNA with a single nucleotide mismatch distinguishes mutant from wild-type nucleic acid templates. Given the proximity between the E484K and N501Y mutations, two primer sets (flanking L452R and E484K/N501Y, respectively) were designed with annealing temperatures similar to or above probe annealing temperatures.

Recognizing the potential for mutations in the targets, on January 26, 2021 we downloaded all available SARS-CoV-2 sequences from GISAID annotated as B.1.1.7 (n=7,864), B.1.351 (n=341), or B.1.427/B.1.429 variants (n=622), as well as all available sequences from NCBI collected prior to December 2020 (n=31,016).²² Primer sequences were conserved in >98.8% of all sequences; mutant probe sequences were conserved in >99.7% of variant-specific sequences and were present in only 0.1% of pre-December 2020 NCBI sequences. The wild-type N501 probe sequence was conserved in 99.2% of pre-December 2020 NCBI sequences.

Additional details regarding synthetic controls, oligonucleotides, cycling conditions, fluorescence thresholds, analytical validation, and assay interpretation for reporting are provided in the Supplementary Methods, Supplementary Tables 1-6, and Supplemental Figure 1.

Clinical Specimens

This study included upper respiratory swab specimens collected between December 1, 2020 and March 3, 2021 from patients as part of routine clinical care. All specimens testing positive for SARS-CoV-2 by NAAT with RT-qPCR $C_t \leq 30$ or transcription-mediated amplification relative light units (RLU) $\geq 1,100$ during this period were subject to multiplex allele-specific genotyping RT-qPCR. All tests were conducted at the Stanford Clinical Virology Laboratory, which serves tertiary-care academic hospitals and affiliated outpatient facilities in the San Francisco Bay Area. After development and analytical validation of our genotyping RT-qPCR, we retrospectively screened all eligible positive specimens dating back to December 1, 2020, and then began prospective genotyping on February 19, 2021. This study was

conducted with Stanford institutional review board approval (protocol 48973), and individual consent was waived.

Prior to genotyping RT-qPCR, initial respiratory SARS-CoV-2 NAAT was conducted on a variety of platforms (Table 1, Supplementary Methods).^{23–25} All assays were conducted according to manufacturer and emergency authorization instructions.^{26,27}

Assay Validation with Next-Generation Sequencing

A subset of wild-type and mutant specimens genotyped by RT-qPCR were confirmed by WGS in a validation dataset. We adapted an existing WGS pipeline for poliovirus genotyping to conduct SARS-CoV-2 whole-genome amplicon-based sequencing (Supplementary Methods).^{28–30} Pangolin was used for PANGO lineage assignment, while Nextclade v0.14.2 and auspice.us 0.5.0. were used to assign Nextstrain clades and perform phylogenetic placement.^{2,30,31} PANGO lineage names and Nextstrain clade names were assigned as of April 5, 2021.

Statistical Analysis

Baseline continuous data were compared with t-tests or Wilcoxon rank-sum tests, whereas categorical data were compared with Fisher exact tests. Positive percent agreement (PPA) and negative percent agreement (NPA) were reported with Clopper-Pearson score 95% binomial confidence intervals using next-generation sequencing as the reference method. Analyses were conducted using the R statistical software package. This study was reported in accordance with STARD guidelines.³²

RESULTS

Population-Level Screening Results

During the period between December 1, 2020 and March 3, 2021, our clinical virology laboratory reported 165,501 negative and 13,083 positive SARS-CoV-2 NAATs among 119,154 unique patients. These 13,083 positive NAATs corresponded to 11,635 patients (Table 1). We assumed this reflected approximately 11,635 unique infections, presuming no re-infection during the study period.

After triaging specimens with higher viral load and sufficient remaining material, we screened 4,049 specimens from unique patients by genotyping RT-qPCR (Table 1, Figure 1). Amplification curves from RT-qPCR were interpreted according to Supplementary Table 4, with example cases presented in Supplementary Figure 2. A total of 174 specimens had amplification failure on initial RT-qPCR, either due to low viral load, amplification failure, or reaction setup error. Among these specimens, 59 were successfully genotyped on repeat RT-qPCR and are included in the analysis dataset, while the remaining 115 were unable to genotype, corresponding to an assay failure rate of 2.8%. Among initial diagnostic

specimens tested by RT-qPCR with available C_t values (3,142), median viral load was significantly lower among samples unable to genotype (C_t 28.8 vs 18.8, $p<0.001$).

Among the 3,934 genotyped specimens, we identified 1,567 (38.7%) with isolated L452R mutations, 34 (0.84%) with isolated N501Y mutations, 22 (0.54%) with isolated E484K mutations, and 3 (0.07%) with E484K+N501Y mutations.

Assay Validation with Next-Generation Sequencing

In addition to validating the assay's analytical performance (Supplementary Tables 5-6), we assessed clinical positive (PPA) and negative percent agreement (NPA) of genotyping RT-qPCR using WGS as a reference method. Among 229 specimens from unique patients assessed by both RT-qPCR and WGS (Table 1), PPA of RT-qPCR for L452R, E484K, and N501Y were: 100% (95% CI 95-100%), 100% (95% CI 80-100%), and 100% (95% CI 86-100%), respectively (Table 2). There were no false negatives by RT-qPCR for L452R, E484K, or N501Y. Furthermore, there were no false positives for E484K (NPA: 100%, 95% CI 98-100%) or N501Y (NPA: 100%, 95% CI 98-100%).

There were three specimens positive for L452R by RT-qPCR but negative for by WGS (NPA: 98%, 95% CI 95-99%). These had L452R C_t values of 20.0, 22.8, and 31.2 with appropriate amplification curves and appropriate N501 wild-type (Cy3.5) internal control amplification (C_t 21.0, 18.4, 30.0). Sequencing coverage and codon calls at the L452 loci were 1,890/1,907 (99%), 2,407/2,424 (99%), and 2,817/2,841 (99%) for these three specimens, which were assigned lineages of B.1.1.222, B.1.2, and B.1.243, respectively. All three specimens were re-extracted and repeated by RT-qPCR with the same result.

Among the 229 specimens tested by both RT-qPCR and WGS, the distribution of PANGO lineages is presented in Table 3, and a phylogenetic tree of Nextstrain clades is presented in Figure 2. The 120 specimens which were wild-type by RT-qPCR were most commonly assigned lineages of B.1.2 (34%) and B.1 (12%). Among the 70 specimens with isolated L452 mutations by RT-qPCR, 43 (60%) and 23 (33%) were B.1.427 and B.1.429, respectively. Among the 22 specimens with isolated N501Y mutations by RT-qPCR, 17 (77%) were B.1.1.7. Among the 14 specimens with isolated E484K mutations by RT-qPCR, 11 (79%) were P.2, 2 (14%) were B.1, and 1 (7%) was B.1.526 (Figure 3). The three specimens with E484K+N501Y mutations were all of B.1.351 lineage. Sequencing quality measures and GISAID accessions are provided in Supplementary Tables 7-8.

Epidemiologic Emergence of L452R

During the study period, we observed rapid emergence of the L452R mutation in our population (Figure 4, Table 4). The majority of such specimens assessed by WGS were B.1.427/B.1.429 variants (93%). Although the number of new infections in our population decreased between January and March 2021,

the proportion of new infections harboring the L452R mutation increased from 24.8% in December 2020 to 62.5% in March 2021.

DISCUSSION

Rapid, accessible, and high-throughput epidemiologic surveillance for SARS-CoV-2 variants is of public health interest. We describe a one-step multiplex RT-qPCR assay that facilitated screening of approximately 4,000 unique infections during a period of high transmission in the San Francisco Bay Area. This assay had excellent concordance with WGS and revealed rapid emergence of variants harboring L452R. In contrast to WGS, the widely-available equipment, resources, and trained personnel make this RT-qPCR assay accessible to nearly all laboratories already offering SARS-CoV-2 NAATs. All current CDC-classified variants of concern (B.1.1.7, P.1, B.1.351, B.1.427, B.1.429) and most variants of interest (P.2, B.1.525, some but not all B.1.526) harbor at least one of the L452R, E484K, or N501Y spike protein mutations, enabling population-level triaging by RT-qPCR to centers performing WGS for lineage determination. This approach has implications for outbreak surveillance, diagnostic testing, transmissibility, virulence, and vaccine and/or antiviral efficacy.

The CDC, ECDC, and WHO have identified multiple SARS-CoV-2 lineages as variants of concern (VOC) or variants of interest (VOI).^{19–21} Many of these variants share the E484K mutation (B.1.351, B.1.525, some B.1.526, P.1, P.2), N501Y mutation (B.1.1.7, B.1.351, P.1), and/or the L452R mutation (B.1.427, B.1.429). Previously-reported studies guided by large-scale genomic surveillance have suggested increased transmissibility, virulence, or reduced vaccine/antiviral efficacy/neutralization corresponding to the phenotypic significance of these spike protein mutations.^{4–17} Moreover, mutations in the spike gene (S gene) may lead to false negative NAAT results.¹⁸

While whole-genome sequencing is required to confirm infection with a specific variant, not all centers have the required resources or personnel to conduct large-scale variant genotyping on a high proportion of incident cases. Allele-specific NAAT-based methods are an alternative to large-scale sequencing programs, but few methods have been described. Korukluoglu et al. recently described a one-step RT-qPCR assay to detect the N501Y and HVdel69-70 using allele-specific forward primers, reserving ORF1ab as an internal control.³³ This assay is conducted in two separate reactions, with the first targeting N501, ORF1ab, and HV69-70del, while the second amplifies N501Y, ORF1ab, and HV69-70del. The authors described high concordance (100%) with Sanger and next-generation sequencing. A disadvantage of this method is the absence of screening for E484K and the requirement for two separate reactions. More recently, Banada et al. reported an RT-qPCR method for detection of N501Y using melt curve analysis.³⁴ This assay includes allele-specific molecular beacon probes for N501 and N501Y conjugated to different fluorophores, similar to our assay. Twenty patient specimens were tested and a subset were confirmed by Sanger sequencing.

Vogels et al. have also described an RT-qPCR assay to detect the ORF1ab 3675-3677 and spike HV69-70 deletions.³⁵ The deletions are detected via ORF1ab-Cy5 and spike-HEX probe dropout, reserving the CDC N1 primer/probe set as an internal control. This assay was concordant with 76 sequenced specimens. Limitations of this assay, as described by the authors, are N1-FAM autofluorescence leading to false B.1.1.7 drop-out and absence of the ORF1ab 3675-3677 deletion in select B.1.351 isolates. While these deletions are surrogates for B.1.1.7, B.1.351, and P.1, screening for N501Y and E484K may be more specific to variants of concern/interest and appear to be causally-associated with concerning phenotypes. Another genotyping NAAT utilized a two-step approach combining the CDC-based laboratory-developed RT-qPCR and the ThermoFisher TaqPath COVID-19 RT-PCR.³⁶ With the intent to identify B.1.1.7 variants, the authors screened 1,035 samples for TaqPath S gene dropout and genotyped two specimens by multiplex droplet digital PCR amplifying HV69-70del, N501Y, del145, and S982A in two reactions, which were positive for these four mutations. Next-generation sequencing confirmed B.1.1.7 lineage. Limitations of this genotyping approach include dependence upon S gene dropout followed by more labor-intensive ddPCR.

The largest NAAT-based genotyping series thus far was a national effort in France recently reported by Haim-Boukobza et al.³⁷ The authors used two separate assays to screen for the HVdel69-70 and N501Y mutations in 35,208 samples, with an uninterpretable assay rate of 19.0% and sequencing concordance Kappa coefficient of 0.87-0.88.

To our knowledge, the present study is the largest NAAT-based SARS-CoV-2 genotyping initiative in the United States. While large multi-institutional programs such as the United Kingdom COVID-19 genomics consortium have sequenced more than 250,000 specimens, many public health systems or private institutions are unable to conduct high-throughput genotyping due to the required cost, equipment, and expertise. The RT-qPCR assay we describe is accessible to any laboratory conducting RT-qPCR SARS-CoV-2 testing, and shares much of the same equipment and reagents. Specimens positive for SARS-CoV-2 by initial NAAT can be rapidly genotyped within hours using the same extracted nucleic acid, and the cost of this assay's custom oligonucleotides are less than one U.S. Dollar per reaction. As proof of concept, we have validated this assay on various qPCR instruments and master mixes, demonstrating that individual laboratories may adapt this assay to existing NAAT workflows.

As evidence of the feasibility of high-throughput testing, we rapidly implemented reflex genotyping RT-qPCR for positive specimens and screened more than 4,000 infections, thereby facilitating local surveillance of L452R mutation emergence. Our results are consistent with a large-scale whole-genome sequencing initiative of 2,172 specimens from 44 counties in California.¹² This series suggested a 19-24% increase in transmissibility relative to wild-type circulating strains, and was the basis for L452R

surveillance in our study. Due to the local prevalence of circulating L452R mutations, our screening initiative identified approximately 1,500 unique infections harboring L452R mutations.

This assay has several limitations. Sporadic isolated L452R, E484K, and N501Y mutations are well-described and are not necessarily indicative of VOC/VOI. For example, in our series of 229 sequenced specimens genotyped by RT-qPCR, isolated E484K or N501Y mutations by PCR were VOC/VOI in 86% and 77% of cases, respectively, while the remaining were uncommon variants. Although our assay does not screen for several other mutations of interest (HVdel69-70, K417N, P681H, Y453F), it is advantageous that such variants are screen-detected via N501Y (B.1.1.7: del69-70, P681H), E484K (P.1 and B.1.351: K417N), and/or L452R. An additional limitation is the lack of wild-type probes for L452 and E484. Although this choice was intentional to maximize efficiency, it introduces the possibility that synonymous or alternate non-synonymous mutations (e.g. E484Q) within the probe binding site could lead to an erroneous result. Lastly, variants may develop new mutations in primer and/or probe sites, potentially leading to false negatives. As such, these primer/probe sequences should be regularly checked against all available GISAID sequences, and new VOC/VOI should be monitored for potential assay interference. An additional limitation is exclusion of samples with lower viral load in an effort to successfully genotype. Although our assay failure rate was low (2.8%), analytical sensitivity could be improved by increasing template volume. Although the present series of 4,049 infections is a subset of the 11,635 unique consecutive infections between December 2020 and March 2021, the genotyped population was similar to the overall population (Table 1). Nevertheless, our results may not be necessarily generalizable to all new infections.

We developed and rapidly implemented a one-step multiplex allele-specific RT-qPCR assay to conduct rapid and high-throughput SARS-CoV-2 variant screening in the San Francisco Bay Area. The assay had near-perfect concordance with whole-genome next-generation sequencing and facilitates detection of all common and uncommon variants of concern/interest harboring the L452R, E484K, or N501Y mutations. This approach can be adapted for emerging mutations and implemented in laboratories already conducting SARS-CoV-2 NAAT using existing resources and extracted nucleic acid.

ACKNOWLEDGEMENTS

We sincerely thank the Stanford Clinical Virology Laboratory staff for their dedication and commitment to patient care in the face of unprecedented challenges presented by the COVID-19 pandemic. We also thank the Stanford Protein and Nucleic Acid Facility for oligonucleotide synthesis.

FUNDING/CONFLICTS OF INTEREST

The authors report no conflicts of interest related to this work.

REFERENCES

1. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043
2. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinforma Oxf Engl*. 2018;34(23):4121-4123. doi:10.1093/bioinformatics/bty407
3. Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology of SARS-CoV-2. *Curr Biol*. 2020;30(15):R849-R857. doi:10.1016/j.cub.2020.06.031
4. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. Published online March 3, 2021. doi:10.1126/science.abg3055
5. Galloway SE. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70. doi:10.15585/mmwr.mm7003e2
6. Muik A, Wallisch A-K, Sängler B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*. 2021;371(6534):1152-1153. doi:10.1126/science.abg6105
7. Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2 | medRxiv. Accessed March 29, 2021. <https://www.medrxiv.org/content/10.1101/2021.02.16.21251535v1>
8. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv*. Published online January 4, 2021:2020.12.30.20249034. doi:10.1101/2020.12.30.20249034
9. Resende PC, Gräf T, Paixão ACD, et al. A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil. *bioRxiv*. Published online March 13, 2021:2021.03.12.434969. doi:10.1101/2021.03.12.434969
10. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med*. Published online February 8, 2021. doi:10.1038/s41591-021-01270-4
11. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology. Virological. Published January 11, 2021. Accessed March 29, 2021. <https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585>
12. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. *medRxiv*. Published online March 9, 2021:2021.03.07.21252647. doi:10.1101/2021.03.07.21252647
13. Madhi SA, Baillie V, Cutland CL, et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. *medRxiv*. Published online February 12, 2021:2021.02.10.21251247. doi:10.1101/2021.02.10.21251247
14. Wang P, Wang M, Yu J, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv*. Published online March 2, 2021:2021.03.01.433466. doi:10.1101/2021.03.01.433466
15. Emary KRW, Golubchik T, Aley PK, et al. *Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)*. Social Science Research Network; 2021. doi:10.2139/ssrn.3779160
16. Collier DA, Marco AD, Ferreira IATM, et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. *medRxiv*. Published online February 15, 2021:2021.01.19.21249840. doi:10.1101/2021.01.19.21249840
17. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. *bioRxiv*. Published online January 29, 2021:2021.01.27.428516. doi:10.1101/2021.01.27.428516
18. Health C for D and R. Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care Providers. *FDA*. Published online January 8, 2021. Accessed March 29, 2021.

377 [https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-](https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2)
378 [lead-false-negative-results-molecular-tests-detection-sars-cov-2](https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2)

379 19. CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published
380 February 11, 2020. Accessed March 29, 2021. [https://www.cdc.gov/coronavirus/2019-ncov/cases-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
381 [updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)

382 20. Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in
383 the EU/EEA, 14th update. European Centre for Disease Prevention and Control. Published
384 February 15, 2021. Accessed March 29, 2021. [https://www.ecdc.europa.eu/en/publications-](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021)
385 [data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021)

386 21. Weekly epidemiological update on COVID-19 - 30 March 2021. Accessed April 5, 2021.
387 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-2021)
388 [2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-2021)

389 22. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to
390 global health. *Glob Chall Hoboken NJ*. 2017;1(1):33-46. doi:10.1002/gch2.1018

391 23. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-
392 time RT-PCR. *Eurosurveillance*. 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045

393 24. Bulterys PL, Garamani N, Stevens B, et al. Comparison of a laboratory-developed test targeting the
394 envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2. *J Clin Virol*
395 *Off Publ Pan Am Soc Clin Virol*. 2020;129:104427. doi:10.1016/j.jcv.2020.104427

396 25. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community
397 Transmission of SARS-CoV-2. *JAMA*. 2020;323(19):1967-1969. doi:10.1001/jama.2020.5445

398 26. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 | FDA. Accessed March
399 31, 2021. [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)
400 [authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)
401 [2#individual-molecular](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)

402 27. Stanford Health Care Clinical Virology Laboratory. Food and Drug Administration Emergency Use
403 Authorization: SARS-CoV-2 RT-PCR Assay. Accessed March 14, 2021.
404 <https://www.fda.gov/media/136818/download>.

405 28. Sahoo MK, Holubar M, Huang C, et al. Detection of Emerging Vaccine-Related Polioviruses by
406 Deep Sequencing. *J Clin Microbiol*. 2017;55(7):2162-2171. doi:10.1128/JCM.00144-17

407 29. Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR method for MinION and Illumina sequencing
408 of Zika and other virus genomes directly from clinical samples. *Nat Protoc*. 2017;12(6):1261-1276.
409 doi:10.1038/nprot.2017.066

410 30. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2
411 lineages to assist genomic epidemiology. *Nat Microbiol*. 2020;5(11):1403-1407.
412 doi:10.1038/s41564-020-0770-5

413 31. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus*
414 *Evol*. 2018;4(1). doi:10.1093/ve/vex042

415 32. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An Updated List of Essential Items for
416 Reporting Diagnostic Accuracy Studies. *Radiology*. 2015;277(3):826-832.
417 doi:10.1148/radiol.2015151516

418 33. Korukluoglu G, Kolukirik M, Bayrakdar F, et al. 40 Minutes RT-QPCR Assay for Screening Spike
419 N501Y and HV69-70del Mutations. *Microbiology*; 2021. doi:10.1101/2021.01.26.428302

420 34. Banada P, Green R, Banik S, et al. A Simple RT-PCR Melting temperature Assay to Rapidly Screen
421 for Widely Circulating SARS-CoV-2 Variants. *MedRxiv Prepr Serv Health Sci*. Published online
422 March 8, 2021. doi:10.1101/2021.03.05.21252709

423 35. Vogels CBF, Breban MI, Alpert T, et al. PCR Assay to Enhance Global Surveillance for SARS-CoV-
424 2 Variants of Concern. *Infectious Diseases (except HIV/AIDS)*; 2021.
425 doi:10.1101/2021.01.28.21250486

426 36. Perchetti GA, Zhu H, Mills MG, et al. Specific allelic discrimination of N501Y and other SARS-CoV-2
427 mutations by ddPCR detects B.1.1.7 lineage in Washington State. *medRxiv*. Published online March
428 12, 2021:2021.03.10.21253321. doi:10.1101/2021.03.10.21253321

429 37. Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, et al. Early Release - Detecting Rapid
430 Spread of SARS-CoV-2 Variants, France, January 26–February 16, 2021 - Volume 27, Number 5—
431 May 2021 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2705.210397

TABLES

Table 1. Patient Characteristics and Aggregate Genotyping RT-qPCR Screening Results During Study Period

Characteristic	All SARS-CoV-2 Infections	RT-qPCR Population	WGS Validation Subset
Patients	11,636	4,049	229
Age at First Positive NAAT	36 [23-52]	37 [23-53]	37 [23-52]
Female	6,009 (51.64%)	2,065 (51.00%)	128 (55.90%)
Initial Diagnostic Specimen	-	-	-
Month of Diagnosis	-	-	-
December 2020	6,074 (52.20%)	344 (8.50%)	18 (7.86%)
January 2021	4,381 (37.65%)	3,050 (75.33%)	170 (74.24%)
February 2021	1,119 (9.62%)	640 (15.80%)	37 (16.16%)
March 2021	62 (0.53%)	15 (0.37%)	4 (1.75%)
Specimen Collection Site	-	-	-
Outpatient COVID-19 Screening Site	6,187 (53.18%)	2,393 (59.10%)	138 (60.26%)
Emergency Department	2,633 (22.62%)	704 (17.39%)	34 (14.85%)
Outpatient Laboratory	1,190 (10.23%)	469 (11.58%)	24 (10.48%)
Occupational Health	628 (5.40%)	123 (3.04%)	6 (2.62%)
Outpatient Clinic	564 (4.85%)	210 (5.19%)	20 (8.73%)
Urgent Care	220 (1.89%)	75 (1.85%)	6 (2.62%)
Inpatient Floor	154 (1.32%)	55 (1.36%)	1 (0.43%)
Perioperative/Periprocedural	28 (0.24%)	11 (0.27%)	0 (0.00%)
Intensive Care Unit	20 (0.17%)	4 (0.10%)	0 (0.00%)
Infusion Center	10 (0.09%)	3 (0.07%)	0 (0.00%)
Home Healthcare	2 (0.02%)	2 (0.05%)	0 (0.00%)
Specimen Source	-	-	-
Nasopharyngeal Swab	6,607 (56.78%)	1,965 (48.51%)	115 (50.22%)
Mid-Turbinate Nasal Swab	4,893 (42.05%)	2,077 (51.30%)	111 (48.48%)
Other	136 (1.17%)	7 (0.17%)	3 (1.30%)
NAAT Platform	-	-	-
PerkinElmer-Based RT-qPCR	7,004 (60.19%)	2,798 (69.10%)	157 (68.56%)
Lab-Developed RT-qPCR	2,418 (20.78%)	610 (15.07%)	44 (19.21%)
Hologic Panther	1,219 (10.48%)	353 (8.72%)	25 (10.92%)
Cepheid GeneXpert	573 (4.92%)	147 (3.63%)	1 (0.44%)
Roche Liat	320 (2.75%)	97 (2.40%)	0 (0.00%)
Genmark Eplex	102 (0.88%)	44 (1.09%)	2 (0.87%)
RT-qPCR Genotype	-	-	-
L452, E484, N501	-	2,308 (57.00%)	120 (52.40%)
L452R, E484, N501	-	1,567 (38.70%)	70 (30.57%)
L452, E484K, N501	-	22 (0.54%)	14 (6.11%)
L452, E484, N501Y	-	34 (0.84%)	22 (9.61%)
L452, E484K, N501Y	-	3 (0.07%)	3 (1.30%)
Unable to Genotype ^a	-	115 (2.84%)	0 (0.00%)

NAAT, nucleic acid amplification test; WGS, whole genome next-generation sequencing

^a Low viral load, amplification failure, or reaction set-up failure despite repeat.

439 **Table 2.** Genotyping RT-qPCR Validation Against Whole-Genome Next-Generation Sequencing
440

RT-qPCR	Whole-Genome Next-Generation Sequencing					
	L452R		E484K		N501Y	
	Detected	Not Detected	Detected	Not Detected	Detected	Not Detected
Detected	67	3 ^a	17	0	25	0
Not Detected	0	159	0	212	0	204
PPA (95% CI) ^b	100% (95-100%)	-	100% (80-100%)	-	100% (86-100%)	-
NPA (95% CI) ^b	-	98% (95-99%)	-	100% (98-100%)	-	100% (98-100%)

CI, confidence interval; PPA, positive percent agreement; NPA, negative percent agreement.
^a Three specimens positive for L452R by RT-qPCR but negative for L452R by sequencing. Further characterization of these samples provided in results.
^b RT-qPCR relative to next-generation sequencing.

441

442 **Table 3.** PANGO Lineage Distribution of Screen-Detected Variants by RT-qPCR
443

PANGO Lineage	RT-qPCR Genotype				
	L452R, E484, N501	L452, E484K, N501	L452, E484, N501Y	L452, E484K, N501Y	L452, E484, N501
B.1	2 (3)	2 (14)	1 (5)	0 (0)	14 (12)
B.1.1	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.1.174	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.222	1 (1) ^a	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.228	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
P.2 ^b	0 (0)	11 (79)	0 (0)	0 (0)	0 (0)
B.1.1.291	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.368	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.1.416	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)
B.1.1.432	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.517	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.519	0 (0)	0 (0)	0 (0)	0 (0)	8 (7)
B.1.1.7 ^c	0 (0)	0 (0)	17 (77)	0 (0)	0 (0)
B.1.139	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.2	1 (1) ^a	0 (0)	3 (14)	0 (0)	41 (34)
B.1.232	0 (0)	0 (0)	0 (0)	0 (0)	5 (4)
B.1.234	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)
B.1.239	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.240	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)
B.1.243	1 (1) ^a	0 (0)	0 (0)	0 (0)	6 (5)
B.1.265	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.311	0 (0)	0 (0)	0 (0)	0 (0)	6 (5)
B.1.323	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.351 ^c	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)
B.1.361	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.369	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.375	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.427 ^c	42 (60)	0 (0)	0 (0)	0 (0)	0 (0)
B.1.429 ^c	23 (33)	0 (0)	0 (0)	0 (0)	0 (0)
B.1.453	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.480	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)
B.1.526 ^b	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)
B.1.561	0 (0)	0 (0)	0 (0)	0 (0)	4 (3)
B.1.565	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.568	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.577	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.596	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.599	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Total	70	14	22	3	120

Data presented as n (column %)
^a Three specimens positive for L452R by RT-qPCR but negative for L452R by next-generation sequencing.
^b CDC-classified variants of interest
^c CDC-classified variants of concern

Table 4. Local Epidemiologic Emergence of L452R

Week of Year, 2020-2021	Total New Infections Genotyped ^a	L452R Infections
Weeks 49-52: 2020-12-01 to 2020-12-31 ^b	476	118 (24.8%)
Week 1: 2021-01-01	905	300 (33.1%)
Week 2: 2021-01-08	888	330 (37.2%)
Week 3: 2021-01-15	598	267 (44.6%)
Week 4: 2021-01-22	329	141 (42.9%)
Week 5: 2021-01-29	265	145 (54.7%)
Week 6: 2021-02-05	199	102 (51.3%)
Week 7: 2021-02-12	120	70 (58.3%)
Week 8: 2021-02-19	106	64 (60.4%)
Week 9: 2021-02-26	48	30 (62.5%)
Total	3,934	1,567 (39.8%)

^a Confirmed by nucleic acid amplification testing, with diagnosis date assigned by first positive test date.

^b Grouped due to fewer tested specimens in early December 2020.

^c Proportion of cases in each week positive for L452R.

FIGURE LEGENDS

Figure 1. Flow chart of specimens sent for nucleic acid amplification tests (NAAT) during the study period and number of specimens ultimately genotyped by multiplex RT-qPCR. *Predominantly specimens with insufficient material, low viral load ($C_t > 30$, $RLU < 1,100$) or positive specimens in December prior to universal institution-wide genotyping.

Figure 2. Nextclade phylogenetic tree of 2,130 SARS-CoV-2 genomes, including 225 of the 229 sequenced genomes from this study, and 1,905 genomes from the Nextstrain global reference tree (left panel). There were 3 sequenced genomes excluded due to discordance between PCR and sequencing, and 1 genome excluded due to insufficient quality to assign a clade. The 225 included genomes are colored by RT-qPCR genotyping result, with each circle representing a sequenced genome. Branch length corresponds to nucleotide divergence. Arrowheads point to mutations identified either sporadically, or in rare lineages. Isolates with N501Y mutations predominantly belong to clade 20I/501Y.V1 and lineage B.1.1.7, though sporadic mutations are noted in clade 20G lineage B.1.2 (top three green arrowheads) and clade 20A lineage B.1.480 (bottom green arrowhead). In addition to the clade 20B lineage P.2 variant of concern, E484K RT-qPCR also identified a clade 20C lineage B.1.526 variant of interest (top two yellow arrowheads), as well as a clade 20A proposed lineage B.1 (bottom yellow arrowhead). Isolates with L452R mutation (turquoise) belong predominantly to clade 20C, and lineages B.1.429 and B.1.427 (right panel). Sporadic L452R mutation was noted within one sample belonging to clade 20A lineage B.1 (turquoise arrowhead). PANGO lineage names and Nextstrain clade names were assigned as of April 5, 2021.

Figure 3. Nextclade phylogenetic tree from Figure 2 magnified to visualize isolates with E484K mutations in clade 20B lineage P.2 (left panel), and isolates with combined N501Y+E484K mutations, all of which belong to clade 20H/501Y.V2 lineage B.1.351 (right panel). They are shown next to their nearest neighbors from the Nextstrain global reference tree, with branch length corresponding to nucleotide divergence. PANGO lineage names and Nextstrain clade names were assigned as of April 5, 2021.

Figure 4. Local epidemiologic emergence of L452R mutations in our genotyped population of 3,934 from December 2020 to March 2021. Bar plot and left y-axis represent number of new unique genotyped infections by week grouped by RT-qPCR-defined genotype. Scatter plot and right y-axis represents proportion of new unique genotyped infections with L452R genotype, with 95% Clopper-Pearson confidence interval.